Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2008-03-04

Clinical Trial Update: EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome [Phase 1]

View source ↗

Summary

Phase 1 trial update of EYE001 for treating retinal tumors in patients with von Hippel-Lindau disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EYE001

Snippet

Sponsor: National Eye Institute (NEI) | Conditions: Hippel-Lindau Disease | Phase 1 | Status: COMPLETED